Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Tzanakaki, Georgina ^a   Hong, Eva ^b   Kesanopoulos, Konstatinos ^a   Xirogianni, Athanasia ^a   Bambini, Stefania ^c   Orlandi, Luca ^c   Comanducci, Maurizio ^c   Muzzi, Alessandro ^c   Taha, Muhamed Kheir ^b  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b INSTITUT PASTEUR   (France)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

4CMenB vaccine; MATS; Meningococcal disease; Vaccine; Vaccine coverage

Indexed keywords

COMPLEMENT FACTOR H; MENINGOCOCCUS VACCINE; NEISSERIA ADHESIN A; NEISSERIAL HEPARIN BINDING ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GREECE; MICROBIAL DIVERSITY; MOLECULAR CLONING; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

NEISSERIA;

EID: 84900847800     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-14-111     Document Type: Article

References (38)

1. Epidemic meningococcaemia, and Neisseria meningitidis. Stephens DS, Greenwood B, Brandtzaeg P, Lancet 2007 369 2196 2210 10.1016/S0140-6736(07) 61016-2 17604802
2. Neisseria meningitidis group B correlates of protection and assay standardization. International meeting report Emory University, Atlanta, Georgia, United States. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D, Vaccine 2006 24 5093 5107 10.1016/j.vaccine.2006.03.091 16838413
3. An IgG monoclonal antibody to group B meningococci cross reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. Finne J, Bitter-Suermann D, Goridis C, Finne U, J Immunol 1987 138 4402 4407 3108388
4. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Finne J, Leinomen M, Makela PH, Lancet 1983 2 355 357 6135869
5. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D, Vaccine 2005 23 2191 2196 10.1016/j.vaccine.2005.01.063 15755593
6. Functional and specific antibody responces in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Wedege E, Bolstad K, Aase A, Herstad TK, McCallum L, Rosenqvist E, Oster P, Martin D, Clin Vaccine Immunol 2007 14 830 838 10.1128/CVI.00039-07 17494638
7. Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M, J Exp Med 2003 197 6 789 799 10.1084/jem.20021911 12642606
8. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, O'Dwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Aricò B, Proc Natl Acad Sci U S A 2010 107 8 3770 3775 10.1073/pnas.0915162107 20133713
9. NadA, a novel vaccine candidate of Neisseria meningitidis. Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Aricò B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M, J Exp Med 2002 195 1445 1454 10.1084/jem.20020407 12045242
10. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P, Clin Vaccine Immunol 2011 18 3 483 486 10.1128/CVI.00304-10 21177912
11. Advances in the development of vaccines against Neisseria meningitidis. Tan LK, Carlone GM, Borrow R, N Engl J Med 2010 362 1511 1520 10.1056/NEJMra0906357 20410516
12. Efficacy of meningococcal serogroup C conjugate vaccines in teenagers and toddlers in England. Ramsey ME, Andrews N, Kaczsmarki EB, Miller E, Lancet 2001 357 195 196 10.1016/S0140-6736(00)03594-7 11213098
13. Meningococcal polysaccharide-protein conjugate vaccines. Snape MD, Pollard AJ, Lancet Infect Dis 2005 5 21 30 10.1016/S1473-3099(04)01251-4 15620558
14. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Borrow R, Andrews N, Goldblatt D, Miller E, Infect Immun 2001 69 3 1568 1573 10.1128/IAI.69.3.1568-1573.2001 11179328
15. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England. Andrews N, Borrow R, Miller E, Clin Diagn Lab Immunol 2003 10 5 780 786 12965904
16. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Sakou I, Tzanakaki G, Tsolia MN, Sioumala M, Barbouni A, Kyprianou M, Papaevangelou V, Tsitsika A, Blackwell CC, Kafetzis D, Kremastinou J, Vaccine 2009 27 33 4408 4411 10.1016/j.vaccine.2009.05.047 19500554
17. Genetics shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Bai X, Borrow R, Expert Rev Vaccines 2010 9 10 1203 1217 10.1586/erv.10.116 20923270
18. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Frasch CE, Borrow R, Donnelly J, Vaccine 2009 27 2 112 B116 19464093
19. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM, Proc Natl Acad Sci U S A 2010 107 19490 19495 10.1073/pnas.1013758107 20962280
20. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Ruijne N, Lea RA, O'Hallahan J, Oster P, Martin D, Clin Vaccine Immunol 2006 13 797 801 10.1128/CVI.00038-06 16829618
21. Virulence factors of gram-negative bacteria in sepsis with a focus on Neisseria meningitidis. Livorsi DJ, Stenehjem E, Stephens DS, Contrib Microbiol 2011 17 31 47 21659746
22. Inter-laboratory standardization of the sandwich ELISA designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Plikaytis BD, Stella M, Boccadifuoco G, DeTora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, Ledroit M, Hong E, Taha MK, Ellie K, Rajam G, Carlone GM, Claus H, Vogel U, Borrow R, Findlow J, Gilchrist S, Stefanelli P, Fazio C, Carannante A, Oksnes J, Fritzsønn E, Klem AM, Caugant DA, Abad R, Vázquez JA, et al. Clin Vaccine Immunol 2012 19 10 1609 1617 10.1128/CVI.00202-12 22875603
23. Predicted strain coverage of meningococcal multicomponent vaccine in Europe: a qualitative and quantitative assessment. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, et al. Lancet Infect Dis 2013 13 5 416 425 10.1016/S1473-3099(13)70006-9 23414709
24. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Fidlow J, Borrow R, Medini D, Tsang R, Vaccine 2013 doi:10.1016/j.vaccine.2013.03.063
25. ECDC Surveillance Report, Surveillance of Bacterial invasive Diseases in Europe; 2008/2009 http://www.ecdc.europa.eu/en/publications/Publications/1107- SUR-IBD-2008-09.pdf
26. PorA variable regions of Neisseria meningitidis. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J, Emerg Infect Dis 2004 10 4 674 678 10.3201/eid1004.030247 15200858
27. Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? Clarke SC, Diggle MA, Mölling P, Unemo M, Olcén P, Vaccine 2003 21 19-20 2468 2473 12744880
28. Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic cases. Mölling P, Unemo M, Bäckman A, Olcén P, APMIS 2000 108 7-8 509 516 11167547
29. The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Suker J, Feavers IM, Achtman M, Morelli G, Wang JF, Maiden MC, Mol Microbiol 1994 12 2 253 265 10.1111/j.1365-2958.1994.tb01014. x 8057850
30. NadA diversity and carriage in Neisseria meningitidis. Comanducci M, Bambini S, Caugant DA, Mora M, Brunelli B, Capecchi B, Ciucchi L, Rappuoli R, Pizza M, Infect Immun 2004 72 4217 4223 10.1128/IAI.72.7.4217-4223.2004 15213166
31. Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Jacobsson S, Thulin S, Mölling P, Unemo M, Comanducci M, Rappuoli R, Olcén P, Vaccine 2006 24 2161 2168 10.1016/j.vaccine.2005.11.006 16321460
32. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Borrow R, Clin Vaccine Immunol 2010 17 919 929 10.1128/CVI.00027-10 20375242
33. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M, Vaccine 2009 27 2794 2803 10.1016/j.vaccine.2009.02.098 19428890
34. The VR2 epitope on the PorA p 1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P, Clin Vaccine Immunol 2006 13 4 486 491 10.1128/CVI.13.4.486-491.2006 16603616
35. Distribution of serogroups and Genotypes among disease associated and carried isolates of Neisseria meningitidis from Czech Republic, Greece and Norway. Yazdankhah SP, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M, Alvestad T, Jolley K, Wilson DJ, McCarthy ND, Caugant DA, Maiden MCJ, J Clin Microbiol 2004 42 11 5146 5153 10.1128/JCM.42.11.5146-5153.2004 15528708
36. Variable-number tandem repeat analysis of meningococcal isolates belonging to the sequence type 162 complex. Yazdankhah SP, Kesanopoulos K, Tzanakaki G, Kremastinou J, Caugant DA, J Clin Microbiol 2005 43 9 4865 4867 10.1128/JCM.43.9.4865-4867.2005 16145161
37. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D, Vaccine 2013 31 43 4968 4974 10.1016/j.vaccine.2013.08.006 23954380
38. Transcriptional Regulation of the nadA Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine. Fagnocchi L, Biolchi A, Ferlicca F, Boccadifuoco G, Brunelli B, Brier S, Norais N, Chiarot E, Bensi G, Kroll JS, Pizza M, Donnelly J, Giuliani MM, Delany I, Infect Immun 2013 81 2 560 569 10.1128/IAI.01085-12 23230289